Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Placebo-Controlled, Double-Blind, Crossover, Study of the Pharmacodynamic Effects of CST-103 Co-administered With CST-107 on the Central Nervous System in Subjects With Neurodegenerative Disorders

Next Previous
X
Search
Trial Profile

A Phase II, Randomized, Placebo-Controlled, Double-Blind, Crossover, Study of the Pharmacodynamic Effects of CST-103 Co-administered With CST-107 on the Central Nervous System in Subjects With Neurodegenerative Disorders

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clenbuterol (Primary) ; CST-107 (Primary) ; Nadolol
  • Indications Cognition disorders; Lewy body disease; Neurodegenerative disorders; Parkinson's disease; Sleep disorders
  • Focus Proof of concept; Therapeutic Use
  • Acronyms CLIN-011
  • Sponsors CuraSen Therapeutics

    • Most Recent Events

    • 30 May 2023 Planned End Date changed from 1 Mar 2023 to 31 Jul 2023.
    • 30 Mar 2023 Results presented in the CuraSen Therapeutics Media Release.
    • 28 Feb 2023 Planned End Date changed from 1 Jan 2023 to 1 Mar 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top